Abstract/Summary:

Primary aldosteronism is a common cause of treatment-resistant hypertension. However, evidence from local health systems suggests low rates of testing for primary aldosteronism. The objective of this retrospective cohort study was to evaluate testing rates for primary aldosteronism and evidence-based hypertension management. In a nationally distributed cohort of veterans with apparent treatment-resistant hypertension, testing for primary aldosteronism was rare and was associated with higher rates of evidence-based treatment with MRAs and better longitudinal BP control. The findings reinforce prior observations of low adherence to guideline-recommended practices in smaller health systems and underscore the urgent need for improved management of patients with treatment-resistant hypertension.

Authors: Jordana B. Cohen, Debbie L. Cohen, Daniel S. Herman, John T. Leppert
Keywords: screening, diagnosis, testing rate
DOI Number: 10.7326/M20-4873      Publication Year: 2020

To search for other research papers by topic, keyword, author, or year, please go to our Publications page.

©2021 Primary Aldosteronism Foundation — All Rights Reserved

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.

©2021 Primary Aldosteronism Foundation

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.